IKS

Inventurus Knowledge Solutions Share Price

₹1,620.10 +0.3 (0.02%)

20 Jun, 2025 12:15

SIP TrendupStart SIP in IKS

Start SIP

Performance

  • Low
  • ₹1,598
  • High
  • ₹1,644
  • 52 Week Low
  • ₹1,237
  • 52 Week High
  • ₹2,189
  • Open Price₹1,610
  • Previous Close₹1,620
  • Volume312,215

Investment Returns

  • Over 1 Month + 0.55%
  • Over 3 Month + 8.39%
  • Over 6 Month -17.38%
  • Over 1 Year + 21.9%
SIP Lightning

Smart Investing Starts Here Start SIP with Inventurus Knowledge Solutions for Steady Growth!

Invest Now

Inventurus Knowledge Solutions Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 57.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 27,797
  • P/B Ratio
  • 24
  • Average True Range
  • 82.77
  • EPS
  • 28.33
  • Dividend Yield
  • 0
  • MACD Signal
  • 42.32
  • RSI
  • 49.06
  • MFI
  • 34.35

Inventurus Knowledge Solutions Financials

Inventurus Knowledge Solutions Technicals

EMA & SMA

Current Price
₹1,620.10
+ 0.3 (0.02%)
pointer
  • stock-down_img
  • Bearish Moving Average 9
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹1,650.10
  • 50 Day
  • ₹1,607.07
  • 100 Day
  • ₹1,660.71
  • 200 Day
  • -

Resistance and Support

1635.27 Pivot Speed
  • R3 1,732.53
  • R2 1,705.27
  • R1 1,662.53
  • S1 1,592.53
  • S2 1,565.27
  • S3 1,522.53

What's your outlook on Inventurus Knowledge Solutions?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

IKS Health provides care enablement services through its advanced platform, easing administrative, clinical, and operational tasks for healthcare providers. Serving U.S. clients, its solutions include Revenue Cycle Management, Clinical Support, and Value-Based Care to enhance healthcare delivery.

Inventurus Knowledge Solutions Ltd has an operating revenue of Rs. 2,663.99 Cr. on a trailing 12-month basis. An annual revenue growth of 45% is outstanding, Pre-tax margin of 23% is great, ROE of 27% is exceptional. The company has a reasonable debt to equity of 28%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 10% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 37 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 120 indicates it belongs to a poor industry group of Comml Svcs-Healthcare and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Inventurus Knowledge Solutions Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-15 Audited Results
2025-02-05 Quarterly Results

Inventurus Knowledge Solutions F&O

Inventurus Knowledge Solutions Shareholding Pattern

63.72%
1.71%
0.13%
5.38%
0%
10.93%
18.13%

About Inventurus Knowledge Solutions

  • NSE Symbol
  • IKS
  • BSE Symbol
  • 544309
  • ISIN
  • INE115Q01022

Similar Stocks to Inventurus Knowledge Solutions

Inventurus Knowledge Solutions FAQs

Inventurus Knowledge Solutions share price is ₹1,620 As on 20 June, 2025 | 12:02

The Market Cap of Inventurus Knowledge Solutions is ₹27796.6 Cr As on 20 June, 2025 | 12:02

The P/E ratio of Inventurus Knowledge Solutions is 57.2 As on 20 June, 2025 | 12:02

The PB ratio of Inventurus Knowledge Solutions is 24 As on 20 June, 2025 | 12:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23